Who should take tamoxifen to reduce breast cancer risk?
The decision to take tamoxifen is an individual one. A woman and her doctor must carefully consider the benefits and risks of therapy. At this time, there is no evidence that tamoxifen has a net benefit for women who do not have an increased risk of developing breast cancer. • What is raloxifene and how does it compare to tamoxifen? Raloxifene is a drug approved by the FDA for the prevention and treatment of osteoporosis in postmenopausal women. Raloxifene is also approved by the FDA for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer. The NCI funded the Study of Tamoxifen and Raloxifene (STAR), a clinical trial comparing raloxifene (Evista®) with tamoxifen in preventing breast cancer in postmenopausal women who are at an increased risk of developing the disease. The study found that raloxifene and tamoxifen are equally effective in reducing invasive breast cancer risk in postmenop
